TARS Stock Overview
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.
Tarsus Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$18.50|
|52 Week High||US$31.00|
|52 Week Low||US$10.80|
|1 Month Change||23.50%|
|3 Month Change||40.90%|
|1 Year Change||-28.79%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-10.11%|
Recent News & Updates
Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues
Shareholders in Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) may be thrilled to learn that the analysts have just...
|TARS||US Pharmaceuticals||US Market|
Return vs Industry: TARS underperformed the US Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: TARS underperformed the US Market which returned -11.7% over the past year.
|TARS Average Weekly Movement||6.8%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: TARS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: TARS's weekly volatility (7%) has been stable over the past year.
About the Company
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals, Inc. Fundamentals Summary
|TARS fundamental statistics|
Is TARS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TARS income statement (TTM)|
|Cost of Revenue||US$40.53m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.12|
|Net Profit Margin||-324.23%|
How did TARS perform over the long term?See historical performance and comparison